

thereof.

In addition, Applicant received U.S. Patent No. 6,191,102 titled Use of GLP-1 Analogs and Derivatives Administered Peripherally in Regulation of Obesity. Claim 1 of this issue patent provides:

A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide analog (GLP-1 analog), a glucagon-like peptide derivative (GLP-1 derivative) or a pharmaceutical salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.

Each of these issued claims is directed to a new use of a genus of GLP-1 compounds. The genus is claimed as a Markush group similar to that pending in the present case.

Amendment of the Claims

Claims 1 through 13 are pending. Please add the following new claim:

14. (new) A method of reducing mortality and morbidity after stroke, comprising normalizing blood glucose levels through activation of the GLP-1 receptor in a patient in need thereof.

15. (new) A method of reducing mortality and morbidity after stroke, comprising stimulating insulin sensitivity through activation of the GLP-1 receptor in a patient in need thereof.

Remarks

New Claims 14 and 15 have basis throughout the Specification. For example, on page 23, line 31 an example of a patient in need of treatment is described as one who is incapable of auto-regulation of blood glucose. On page 24,